DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine

Pardi, 2017, Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge, Nat. Commun., 8, 10.1038/ncomms14630 An, 2018, Systemic messenger RNA therapy as a treatment for methylmalonic acidemia, Cell Rep., 24, 2520, 10.1016/j.celrep.2018.08.049 Kose, 2019, A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection, Sci. Immunol., 4, eaaw6647, 10.1126/sciimmunol.aaw6647 Samsa, 2019, Self-amplifying RNA vaccines for Venezuelan equine encephalitis virus induce robust protective immunogenicity in mice, Mol. Ther., 27, 850, 10.1016/j.ymthe.2018.12.013 Foster, 2019, The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy, Mol. Ther., 27, 747, 10.1016/j.ymthe.2019.01.018 Quabius, 2015, Synthetic mRNAs for manipulating cellular phenotypes: An overview, New Biotechnol., 32, 229, 10.1016/j.nbt.2014.04.008 Maruggi, 2019, mRNA as a transformative technology for vaccine development to control infectious diseases, Mol. Ther., 27, 757, 10.1016/j.ymthe.2019.01.020 Leonhardt, 2014, Single-cell mRNA transfection studies: Delivery, kinetics and statistics by numbers, Nanomed. Nanotechnol., 10, 679, 10.1016/j.nano.2013.11.008 Conway, 2019, Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets, Mol. Ther., 27, 866, 10.1016/j.ymthe.2019.03.003 Xiong, 2018, Biomedical applications of mRNA nanomedicine, Nano Res., 11, 5281, 10.1007/s12274-018-2146-1 Zhang, 2019, Genome editing with mRNA encoding ZFN, TALEN, and Cas9, Mol. Ther., 27, 735, 10.1016/j.ymthe.2019.01.014 Warren, 2019, mRNA-based genetic reprogramming, Mol. Ther., 27, 729, 10.1016/j.ymthe.2018.12.009 Sahin, 2017, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature, 547, 222, 10.1038/nature23003 Fotin-Mleczek, 2011, Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity, J. Immunother., 34, 1, 10.1097/CJI.0b013e3181f7dbe8 Melero, 2014, Therapeutic vaccines for cancer: An overview of clinical trials, Nat. Rev. Clin. Oncol., 11, 509, 10.1038/nrclinonc.2014.111 Cafri, 2019, Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer, J. Clin. Oncol., 37, 10.1200/JCO.2019.37.15_suppl.2643 Leal, 2018, Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection, Aids, 32, 2533, 10.1097/QAD.0000000000002026 Gandhi, 2018, Phase 1/2 study of mRNA vaccine therapy plus durvalumab (durva) +/− tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC), J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.TPS9107 Ogris, 1999, PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery, Gene Ther., 6, 595, 10.1038/sj.gt.3300900 Bessis, 2004, Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms, Gene Ther., 11, S10, 10.1038/sj.gt.3302364 Baum, 2006, Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors, Hum. Gene Ther., 17, 253, 10.1089/hum.2006.17.253 Waehler, 2007, Engineering targeted viral vectors for gene therapy, Nat. Rev. Genet., 8, 573, 10.1038/nrg2141 Monopoli, 2012, Biomolecular coronas provide the biological identity of nanosized materials, Nat. Nanotechnol., 7, 779, 10.1038/nnano.2012.207 Lee, 2012, Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery, Nat. Nanotechnol., 7, 389, 10.1038/nnano.2012.73 Kowalski, 2019, Delivering the messenger: advances in technologies for therapeutic mRNA delivery, Mol. Ther., 27, 710, 10.1016/j.ymthe.2019.02.012 Verbeke, 2017, Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA, J. Control. Release, 266, 287, 10.1016/j.jconrel.2017.09.041 Wu, 2014, In vitro and in vivo activities of antimicrobial peptides developed using an amino acid-based activity prediction method, Antimicrob. Agents Chemother., 58, 5342, 10.1128/AAC.02823-14 Zhang, 2018, Novel self-assembled micelles based on cholesterol-modified antimicrobial peptide (DP7) for safe and effective systemic administration in animal models of bacterial infection, Antimicrob. Agents Chemother., 62, e00318, 10.1128/AAC.00368-18 Zhang, 2020, Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens, Biomaterials, 241, 10.1016/j.biomaterials.2020.119852 Zhang, 2018, Delivery of a modified mRNA encoding IL-22 binding protein (IL-22BP) for colon cancer gene therapy, J. Biomed. Nanotechnol., 14, 1239, 10.1166/jbn.2018.2577 Kreiter, 2008, Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals, J. Immunol., 180, 309, 10.4049/jimmunol.180.1.309 Zhang, 2019, Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models, Cancer Immunol. Immun., 69, 135, 10.1007/s00262-019-02448-z Lacerda, 2012, Translocation mechanisms of chemically functionalised carbon nanotubes across plasma membranes, Biomaterials, 33, 3334, 10.1016/j.biomaterials.2012.01.024 Gubin, 2014, Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, 515, 577, 10.1038/nature13988 Steinhagen, 2011, TLR-based immune adjuvants, Vaccine, 29, 3341, 10.1016/j.vaccine.2010.08.002 Sato, 2017, Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus, J. Control. Release, 266, 216, 10.1016/j.jconrel.2017.09.044 Kedmi, 2010, The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation, Biomaterials, 31, 6867, 10.1016/j.biomaterials.2010.05.027 Heath, 2001, Cross-presentation in viral immunity and self-tolerance, Nat. Rev. Immunol., 1, 126, 10.1038/35100512 Lu, 2012, Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans, PLoS One, 7